跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

SML1227

Sigma-Aldrich

Tavaborole

≥95% (HPLC)

别名:

1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, AN-2690, AN2690

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C7H6BFO2
分子量:
151.93
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥95% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 20 mg/mL, clear

储存温度

−20°C

SMILES字符串

B1(OCc2c1ccc(c2)F)O

InChI

1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2

InChI key

LFQDNHWZDQTITF-UHFFFAOYSA-N

一般描述

Tavaborole is a boron-based pharmaceutical agent. It has broad-spectrum oxaborole antifungal activity. Due to its low molecular weight, it facilitates maximal nail plate penetration than its predecessors.

生化/生理作用

Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct with the 3′ adenosine of tRNA(leu) at the editing site of fungal, but not bacterial LeuRS, locking the enzyme in an inactive conformation. Tavaborole was recently approved for the treatment of onychomycosis of the toenail in adults.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
Toledo-Bahena ME, et al.
J. Drugs Dermatol., 13(9), 1124-1132 (2014)
Tavaborole for the treatment of onychomycosis
Elewski BE and Tosti A
Expert Opinion on Pharmacotherapy, 15(10), 1439-1448 (2014)
Spotlight on tavaborole for the treatment of onychomycosis
Jinna S and Finch J
Drug design, development and therapy, 9, 6185-6185 (2015)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门